Research programme: Filovirus immunotherapeutics - Inovio Pharmaceuticals

Drug Profile

Research programme: Filovirus immunotherapeutics - Inovio Pharmaceuticals

Alternative Names: dMAb - Inovio; INO 4200; Protein based therapeutic monoclonal antibody - Inovio; VGX 4200

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Pharmaceuticals
  • Class DNA vaccines; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Ebola virus infections

Highest Development Phases

  • Preclinical Ebola virus infections
  • No development reported Marburg virus disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Marburg virus disease(Prevention) in USA (Intradermal)
  • 08 Apr 2015 Preclinical trials in Ebola virus infections in USA (Parenteral)
  • 14 May 2010 Inovio Biomedical is now called Inovio Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top